CoChat

MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes

Keklikoglou, I, Hosaka, K, Bender, C, Bott, A, Koerner, C, Mitra, D, Will, R, Woerner, A, Muenstermann, E, Wilhelm, H, Cao, Y, Wiemann, S · 2015 · Oncogene
Cited by 108

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/onc.2014.408

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 39

  1. Tuveson DA, Hingorani SR . Ductal pancreatic cancer in humans and mice. Cold Spring Harb Symp Quant Biol 2005; 70: 65–72. · DOI · Paper page
  2. Warshaw AL, Fernandez-del Castillo C . Pancreatic carcinoma. N Engl J Med 1992; 326: 455–465. · DOI · Paper page
  3. Ying H, Elpek KG, Vinjamoori A, Zimmerman SM, Chu GC, Yan H et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-kappaB-cytokine network. Cancer Discov 2011; 1: 158–169. · DOI · Paper page
  4. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ . The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999; 5: 119–127.
  5. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003; 22: 3243–3251. · DOI · Paper page
  6. Fujioka S, Sclabas GM, Schmidt C, Frederick WA, Dong QG, Abbruzzese JL et al. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res 2003; 9: 346–354.
  7. Esquela-Kerscher A, Slack FJ . Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259–269. · DOI · Paper page
  8. du Rieu MC, Torrisani J, Selves J, Al Saati T, Souque A, Dufresne M et al. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem 2010; 56: 603–612. · DOI · Paper page
  9. Munding JB, Adai AT, Maghnouj A, Urbanik A, Zollner H, Liffers ST et al. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma. Int J Cancer 2012; 131: E86–E95. · DOI · Paper page
  10. Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, Shavinskaya A et al. MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kappaB and TGF-beta signaling pathways. Oncogene 2012; 31: 4150–4163. · DOI · Paper page
  11. Donahue TR, Tran LM, Hill R, Li Y, Kovochich A, Calvopina JH et al. Integrative survival-based molecular profiling of human pancreatic cancer. Clin Cancer Res 2012; 18: 1352–1363. · DOI · Paper page
  12. Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG et al. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res 2012; 40: 3689–3703. · DOI · Paper page
  13. Taulli R, Bersani F, Foglizzo V, Linari A, Vigna E, Ladanyi M et al. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest 2009; 119: 2366–2378.
  14. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451: 147–152. · DOI · Paper page
  15. Liou GY, Doppler H, Necela B, Krishna M, Crawford HC, Raimondo M et al. Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-kappaB and MMPs. J Cell Biol 2013; 202: 563–577. · DOI · Paper page
  16. Hofmann I, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V et al. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PloS One 2012; 7: e44146. · DOI · Paper page
  17. Sarkar S, Swiercz R, Kantara C, Hajjar KA, Singh P . Annexin A2 mediates up-regulation of NF-kappaB, beta-catenin, and stem cell in response to progastrin in mice and HEK-293 cells. Gastroenterology 2011; 140: 583–95 e4. · DOI
  18. Zhang G, Schetter A, He P, Funamizu N, Gaedcke J, Ghadimi BM et al. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. PloS One 2012; 7: e31507. · DOI · Paper page
  19. Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ . K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res 2007; 67: 2098–2106. · DOI · Paper page
  20. Zheng L, Foley K, Huang L, Leubner A, Mo G, Olino K et al. Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. PloS One 2011; 6: e19390. · DOI · Paper page
  21. Brownstein C, Deora AB, Jacovina AT, Weintraub R, Gertler M, Khan KM et al. Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages. Blood 2004; 103: 317–324. · DOI
  22. Madureira PA, Surette AP, Phipps KD, Taboski MA, Miller VA, Waisman DM . The role of the annexin A2 heterotetramer in vascular fibrinolysis. Blood 2011; 118: 4789–4797. · DOI
  23. Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM . Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 2004; 172: 2853–2860. · DOI · Paper page
  24. Matsuo Y, Raimondo M, Woodward TA, Wallace MB, Gill KR, Tong Z et al. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer 2009; 125: 1027–1037. · DOI
  25. Miyake M, Goodison S, Urquidi V, Gomes Giacoia E, Rosser CJ . Expression of CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor and the ERK1/2 and EGF pathways. Lab Invest 2013; 93: 768–778. · DOI
  26. Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q et al. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 2006; 203: 941–951. · DOI · Paper page
  27. Bussolino F, Wang JM, Defilippi P, Turrini F, Sanavio F, Edgell CJ et al. Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature 1989; 337: 471–473. · DOI · Paper page
  28. Stamatovic SM, Keep RF, Mostarica-Stojkovic M, Andjelkovic AV . CCL2 regulates angiogenesis via activation of Ets-1 transcription factor. J Immunol 2006; 177: 2651–2661. · DOI · Paper page
  29. Low-Marchelli JM, Ardi VC, Vizcarra EA, van Rooijen N, Quigley JP, Yang J . Twist1 induces CCL2 and recruits macrophages to promote angiogenesis. Cancer Res 2013; 73: 662–671. · DOI · Paper page
  30. Stahlhut C, Suarez Y, Lu J, Mishima Y, Giraldez AJ . miR-1 and miR-206 regulate angiogenesis by modulating VegfA expression in zebrafish. Development 2012; 139: 4356–4364. · DOI
  31. Cao R, Ji H, Feng N, Zhang Y, Yang X, Andersson P et al. Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc Natl Acad Sci USA 2012; 109: 15894–15899. · DOI · Paper page
  32. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7: 192–198. · DOI · Paper page
  33. Tammela T, Alitalo K . Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010; 140: 460–476. · DOI · Paper page
  34. Cao Y . Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer 2005; 5: 735–743. · DOI · Paper page
  35. Sharma M, Blackman MR, Sharma MC . Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model. Exp Mol Pathol 2012; 92: 175–184. · doi:10.1016/j.yexmp.2011.10.003
  36. Wang CY, Chen CL, Tseng YL, Fang YT, Lin YS, Su WC et al. Annexin A2 silencing induces G2 arrest of non-small cell lung cancer cells through p53-dependent and -independent mechanisms. J Biol Chem 2012; 287: 32512–32524. · DOI
  37. Seckinger A, Meissner T, Moreaux J, Depeweg D, Hillengass J, Hose K et al. Clinical and prognostic role of annexin A2 in multiple myeloma. Blood 2012; 120: 1087–1094. · DOI · Paper page
  38. Stupack DG, Cheresh DA . ECM remodeling regulates angiogenesis: endothelial integrins look for new ligands. Sci STKE 2002; 2002: pe7. · DOI · Paper page
  39. Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674. · DOI · Paper page

Cited by

Metadata

Authors
Keklikoglou, I., Hosaka, K., Bender, C., Bott, A., Koerner, C., Mitra, D., Will, R., Woerner, A., Muenstermann, E., Wilhelm, H., Cao, Y., & Wiemann, S.
Venue
Oncogene
Published
2014-12-15
Volume
34
Issue
37
Pages
4867-4878
ISSN
  • 0950-9232
  • 1476-5594
Cited by
108
References
8
Language
en
Licence
creativecommons.org/licenses/by-nc-sa/4.0 (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.